邁克生物(300463.SZ):公司預計將於2025年實現全球化的市場營銷網絡佈局
格隆匯5月5日丨邁克生物(300463.SZ)於2023年4月28日召開業績説明會,就“請領導介紹一下公司未來的整體戰略規劃”,公司表示,公司核心戰略為產品戰略,多年來圍繞這一目標制定了自主產品全產品線佈局的中長期規劃,現已逐步形成了8+1的產品平台,實現產品系列化、系統化、自動化,預計至2024年公司除產品品類齊全外,還將在生免、血球、凝血、尿液上形成流水線從而可提供自主化流水線整體實驗室解決方案,除傳統板塊外,也將加大對新技術、新產品的開發投入。隨着產品實現和產品經營地推進,公司預計將於2025年實現全球化的市場營銷網絡佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.